Moderna (NASDAQ:MRNA) has been the hottest stock in the S&P 500 this year, and it hasn't been close. Up around 650%, the next-best-performing stock is Sandisk, with gains of about 380% thus far. It's been an exceptional performance for Moderna, which struggled in recent years after its sales nosedived as demand for its COVID vaccine and pill dwindled. Now, however, there's plenty of excitement around the business due to the cancer vaccine it's been working on with Merck. And if it can be as successful as Moderna's CEO believes it can be, then it may not be unrealistic to expect the healthcare stock to surge even higher in value.
CryptoAlerta — análise de criptomoedas e mercado em tempo real